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1. Introduction 
1.a History and terminology 
Mixed adeno-neuroendocrine carcinomas (MANECs) represent a group of 
neoplasms including both an epithelial non-neuroendocrine and a neuroendocrine 
component in accordance with the 2010 World Health Organization (WHO) 
classification of tumours of the digestive system (1). The two most important 
diagnostic criteria are: (i) each component has to comprise at least 30% of the whole 
tumour taking into account a thresold arbitrarily proposed in 1987 (2, 3), and (ii) 
both components must be malignant (1).  
Although this mixed (non-neuroendocrine/neuroendocrine) feature is frequently 
observed in routine practice, a true MANEC is rarely found.  
The first description of a gastrointestinal tumour involving both the neuroendocrine 
and exocrine counterpart has been reported by Cordier in 1924(4). Since then, 
various terms including “composite carcinoid”, “mucin-producing carcinoid”, 
“argentaffin cell adenocarcinoma”, “goblet cell carcinoid”, “adenocarcinoid”, “small 
cell undifferentiated carcinoma”, have been used to describe these kind of entities. In 
1987 Lewin observed that, between the classic carcinoid and carcinoma, there was 
also a cluster of distinct tumours, which includes different mixtures of endocrine 
cells and non-endocrine epithelial cells such as “mucin secreting”, “columnar cells”, 
“goblet cells”, and “signet ring cells”. Therefore, these lesions have been called 
“mixed” or “composite” tumours, and have been further divided into three different 
histologic subtypes: “collision tumours”, “combined tumours”, and “amphicrine 
tumours” (3)as shown in Figure 1. In accordance with this classification, all tumours 
containing endocrine and non-endocrine epithelial cells, in whichever amount, could 
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be called “mixed”. However, the authors limited this terminology to those neoplasms 
in which the endocrine component represented between about a third and half of all 
cells. They also used the term “amphicrine tumours”  for lesions in which endocrine 
and non-endocrine epithelial differentiation were present within the same cell. 
Figure 1. (1987) Nomenclature and classification of pure and mixed endocrine cell 
tumours(3). 
 
Over the years the use of this varied terminology led to some confusion among 
clinicians, surgeons, gastroenterologists, and pathologists until the 2000 WHO 
classification of endocrine tumours(5), where these mixed neoplasms were defined 
as “mixed exocrine-endocrine tumours”(6). Later on, they were named “mixed 
adenoneuroendocrine carcinomas” (MANECs) with the 2010 WHO classification of 
neoplasms of the gastrointestinal (GI) tract(1), that defined the 30% threshold 
(Fig.2).  Therefore neither an adenocarcinoma with scattered immunohistochemistry 
(IHC) positive neuroendocrine cells, nor a neuroendocrine neoplasm with a focal 
non-neuroendocrine component can be classified as a MANEC. 
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Figure 2. Schematic representation of neuroendocrine differentiation in human 
tumours: from neuroendocrine neoplasms with a focal exocrine component at one 
extreme (left) to exocrine carcinomas with interspersed neuroendocrine cells at the 
other (right). Mixed exocrine-neuroendocrine tumours (middle) are only those 
neoplasms in which each component represents at least 30% of the lesion (2).  
 
Legend: NE: neuroendocrine; WDET: well differentiated endocrine tumour; TC: typical (lung) 
carcinoid; WDEC: well-differentiated endocrine carcinoma; AC: atypical (lung) carcinoid; PDEC: 
poorly differentiated endocrine carcinoma; LCNEC: large cell neuroendocrine carcinoma; GI: 
gastrointestinal. 
Moreover, La Rosa et al in 2016(7) reported the most important clinico-pathological 
and morphological features of the mixed neuroendocrine-non-neuroendocrine 
epithelial neoplasms observed in the pituitary, thyroid, nasal cavity, larynx, lung, 
digestive system, urinary system, male/female genital organs, and skin, coining the 
term MiNEN. This term was included into the 2017 WHO classification only for 
pancreatic NEN(8) (9). 
It is noteworthy that, the term MANEC in accordance with the 2010 WHO 
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classification (1) still refers to the mixed neuroendocrine-non-neuroendocrine 
epithelial neoplasms of the digestive system and not to all the mixed 
neuroendocrine-non-neuroendocrine epithelial neoplasms. They are defined as 
“carcinomas” since both components are histologically malignant but 
occasionally one or both are low grade. Accordingly the rare tumours composed 
of adenoma and well differentiated neuroendocrine tumour (NET according to 
the nomenclature proposed by the 2010 WHO classification) are not classified into 
the 2010 WHO classification.  
While in some MANECs the neuroendocrine and exocrine components occur in 
separate areas of the same lesion (composite or collision neoplasms), in other 
MANECs they are intimately and diffusely admixed (combined neoplasms). In 
amphicrine tumours exocrine and neuroendocrine features are present in the same 
neoplastic cell, which shows a divergent immunophenotype.  
Goblet cell carcinoids of the appendix are a particular type of mixed exocrine-
neuroendocrine neoplasms. In most cases, their neuroendocrine component does not 
reach 30% and is mostly represented by scattered neuroendocrine cells, therefore 
they are not included in the present paper. However these neoplasms, based on their 
particular clinical and biological features, require further investigation to better 
clarify their histogenesis, molecular profile, and, consequently, a specific 
classification.  
1.b Morphological and prognostic aspects of MANECs 
Since the potential various neuroendocrine and non-neuroendocrine histotypes 
combination, 3 prognostic categories has been previously proposed(6): high grade 
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malignant MANECs (composed of a carcinoma and a NEC component), 
intermediate grade malignant MANECs (including an adenocarcinoma/carcinoma 
as exocrine component and a well differentiated NET), and low grade malignant 
MANECs (composed of an adenoma and a well differentiated NET). 
 
High grade MANECs 
The high grade MANEC is the entity that has been most integrated into the 2010 
WHO 2010(1). 
This is an aggressive composite or combined MANEC formed by a non-NEC 
component and a NEC component. The non-NEC component is formed by a 
carcinomatous (mainly adenocarcinoma, rarely other variant of ordinary carcinomas 
linked to the site of origin; acinic in pancreas or squamous in rectum). The NEC 
component is represented by  poorly differentiated (small, intermediate or large 
cell type) neuroendocrine carcinoma (NEC). MANECs have been observed in the 
esophagus(10), stomach(11), ampullary region(12), large bowel(13), and anorectal 
region(14).  
Macroscopically, these neoplasms, independently of the site of origin, appear as 
polypoid masses or ulcerating stenotic lesions measuring from 0.5 to 14 cm in 
greatest diameter, with a mean size of about 5 cm. Histologically, the NEC 
component is morphologically similar to small cell or large cell NEC of the lung and 
corresponds to a grade 3 neuroendocrine neoplasm, according to the 2010 WHO 
classification(1) . The small cell component has a diffuse or nesting growth pattern 
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and is formed by small to intermediate sized cells with scanty cytoplasm and 
fusiform nuclei with granular chromatin and inconspicuous nucleoli. Diffuse 
geographic necrosis is common. The mitotic rate is high ranging from 20 to 80 
mitotic figures per 10 high-power fields. The large cell component(15), is formed of 
cells with an abundant cytoplasm showing more vesicular nuclei with prominent 
nucleoli as well as a more prominent organoid, trabecular and palisading pattern.  
As for the immunohistochemical aspects it has been reported that the large or small 
neuroendocrine cell counterparts are extensively positive for synaptophysin and, 
although in a lesser way, also for chromogranin A(13, 16, 17). Then, in accordance 
with the 2010 WHO classification for GEP NEN, the diagnosis of MANEC requires 
that the NEN counterpart extensively express two neuroendocrine markers 
(synaptophysin and chromogranin A)(1) and a Ki67 labeling index usually very high 
(60%–90%)(18). Even though without a clear prognostic relevance, a nuclear 
accumulation and immunoreactivity for some other proteins such as P53, CDX2, 
TTF-1, and ASH1 have been observed in NEC(11, 13, 19, 20). Moreover also the 
CD117 immunoreactivity and vascular invasion have been observed in the NEC 
component of some colorectal MANECs and these features were associated with a 
worse prognosis(13). 
The non-neuroendocrine component of high grade MANECs can be represented by 
adenocarcinoma/carcinoma prevalently observed in gastric(20, 21) and colorectal 
MANECs(13, 15, 22) or, more rarely, by squamous cell carcinoma-like in 
esophageal and anorectal MANECs (15, 18, 23).  
The clinical behavior of high grade MANECs is generally aggressive and the 
	   9	  
prognosis depends on biological features(24), and stage(10, 16).  
Moreover, given the lack of prognostic and predictive validated factors, some 
authors suggest that survival differences between MANECs and NECs could depend 
also on the site of origin(8). 
 
Intermediate grade MANECs 
This group include two different tumour categories: mixed adenocarcinoma-
neuroendocrine tumour and amphicrine carcinoma. In the first the exocrine 
component is represented by an adenocarcinoma/carcinoma which can exhibit 
different degrees of differentiation, while the neuroendocrine component is 
represented by a well differentiated neuroendocrine tumour which can show grade 
1 (NET G1) or grade 2 (NET G2) differentiation. This entity, since both components 
are malignant, when referred to the digestive system, is also included in the general 
group of the so called MANECs. The suffix “NECs” present in the term “MANECs”, 
in this case, should be used carefully although it is in line with the criteria proposed 
in the 2010 WHO classification of tumours of the gastrointestinal tract(1). In this 
case the exocrine component is biologically more aggressive than the neuroendocrine 
one.  
The amphicrine carcinoma represents a peculiar tumour in which exocrine and 
neuroendocrine features are co-expressed by the same neoplastic cells, which 
show a divergent differentiation demonstrable with immunohistochemical or electron 
microscopic tools(24).  
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Low grade MANECs or mixed adeno-neuroendocrine tumours (“MANETs”) 
This group of neoplasms include those consisting of both a well differentiated 
neuroendocrine component and an exocrine one which behave in an indolent 
way. They represent a particular entity and the term “MANET” has been previously 
and provisionally proposed but not absorbed nor included in the 2010 WHO 
classification (MANETs)(24). From a morphological point of view, these neoplasms 
appear as polyps ranging from 1.5 to 3 cm in size. While the exocrine part 
histologically consists of an adenomatous component with low or high-grade 
dysplasia, the neuroendocrine component is a low-grade neuroendocrine 
tumour (NET). In some cases the neuroendocrine cells mixs with the adenomatous 
glands (combined tumour), while in other cases the neuroendocrine and exocrine 
components occur in separate areas of the same lesion as separate lesions juxtaposed 
to one other (collision or composite tumour). In this last case, the polyp appears as a 
lesion with the neuroendocrine component in the center and the adenomatous 
component in the periphery of the polyp. Neuroendocrine cells are of small size and 
form solid nests. They have nuclei with stippled chromatin and they lack significant 
atypia or mitotic activity. The neuroendocrine component is chromogranin A and/or 
synaptophysin positive(25, 26). Tumours are generally limited to the mucosa or 
submucosa and they can be removed by endoscopic polypectomy or trans-anal 
excision. These morphological characteristics of these rare neoplasms seem to 
suggest that they are low grade malignant tumours therefore their prognosis seems 
good because no evidence of tumour recurrence has been found in any of the cases 
so far reported(25, 26).  
 
	   11	  
1.c Pathogenesis  
The pathogenesis of MANECs is still debatable with some controversial histogenic 
hypotheses still unconfirmed. In accordance with the two most acknowledged 
theories MANECs may result from either the simultaneous proliferation of multiple 
cell lineages or the proliferation of stem cells that then differentiate along multiple 
cell lineages. In fact the amphicrine entity, which contains within its cytoplasm 
both neuroendocrine secretory granules and mucin droplets, reflects this last 
hypothesis of a common precursor stem cell capable of divergent differentiation 
within an individual neoplastic cell(3, 27).  
 
1.d Recent biological findings and prognosis of MANECs (according to 2010 
WHO classification) 
In a recent retrospective analysis of 160 surgical samples of the digestive system, the 
NEC component, in particular the Ki67 index, was the main prognostic driver(28). 
Therefore the authors found two main prognostic categories(28) on the basis of 
Ki67 index (higher or lower than 55%) of the NEC component. In fact in this 
regard Ki67 index of the NEC component showed to be superior to any other 
parameter among those morphological (prevalence of NEC and non-NEC 
component, presence of small or large cell in NEC component, histotype), 
immunohistochemical (p53, Rb, Bcl-2, p16, Cdx2, MMR deficiency, TTF1, ALDH, 
CD117, SSTR2A protein expression, Ki67 index of the non-NEC component) and 
molecular (TP53, KRAS, BRAF mutations) evaluated. Moreover in this analysis, as 
already observed for pure NEC(29), the survival outcomes were clearly different 
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between MANEC with Ki67 of the NEC component more or less than 55%. 
Moreover the overall survival (OS) of these MANECs with > 55% Ki67 in the NEC 
component seemed to be similar to that of the corresponding pure NECs with Ki67 > 
55% [Type C NECs according to Milione et al. 2017(30)]. On the contrary MANECs 
with < 55% Ki67 showed better survival compared to the pure NECs with 21-55% 
Ki67 [Type B NECs according to Milione et al 2017(30)].   
In the study of Milione et al.(28) the improved survival associated with the 
expression of Rb, p16, p53, Cdx2, CD117, ALDH, MMR in the NEC component 
suggests a possible common origin of the two MANEC counterparts(28) from the 
proliferation of stem cells that go through divergent differentiation during tumour 
progression. Then some other factors such as tumour stage, subtype (amphicrine and 
combined), perineural infiltration, high grade budding, gene mutations, and Ki67 of 
the non-NEC component were significantly associated with survival suggesting a 
their potential prognostic role(28). 
 
1.e Clinical management of MANECs (according to 2010 WHO classification) 
Given the rarity of these entities, the optimal strategy of clinical management of 
MANECs is largely unknown. In general, when considering treatment, it should be 
taken into account to prioritise the more aggressive component of MANECs (24, 31).  
No specific clinical practice guidelines by Oncological or Neuroendocrine (European 
or American) Societies have been yet developed worldwide. A chapter on goblet cell 
carcinoma (which is not within the remit of this dissertation) has been published in 
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the European Neuroendocrine Tumor Society (ENETS) guidelines some years ago 
(2012 version)(32). Furthermore, only a limited number of studies on MANEC have 
been published, mostly retrospective and with a small population.  
Some authors maintain that the prognosis of high grade MANECs, when localized, 
is better than that of pure NECs(33) and that they should undergo radical surgery 
when feasible. This approach has been reported with benefit in terms of survival in 
patients with pancreatic and colo-rectal MANECs(34, 35). Although some 
retrospective data seem to suggest a favourable outcomes (10, 36, 37), the role of 
adjuvant chemotherapy is still undefined and it should be discussed according to 
patient and tumour features.  When metastatic, since the NEC component is, almost 
always, predominant compared to the exocrine part(35), some authors suggest to 
focus therapy on the neuroendocrine component(24, 31). Otherwise, when 
metastases contain a prominent adenocarcinoma component, treatment should be 
similar to that given for “pure” adenocarcinomas(24, 35). In advanced high grade 
neuroendocrine carcinomas the combination regimen cis-carbo/platinum and 
etoposide represents the most common chemotherapy proposed(38); it could be 
offered again if progression occurs more than 3 months from the end of first-line 
therapy(33). Otherwise the use of combinations of 5-fluorouracil and irinotecan(35) 
or temozolomide(33) should be considered in some cases. Moreover, as observed in 
some experiences including patients with NEC from various origins, although 
extrapolating data from studies on mixed population and not designed to focus on 
MANECs,  the combination of 5-fluorouracil and oxaliplatin(39, 40) should be 
evaluated. Long-acting somatostatin analogues (SSAs)(41, 42), peptide-radionuclide 
radiation therapy (PRRT)(43), and biological targeted therapies as everolimus(44, 
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45), and sunitinib(46) should not be used outside clinical trials in patients with high-
grade MANECs as well as  “pure” NECs as they have only been studied and 
approved in low grade NEN populations. 
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2. Study rationale and study design 
2.a Study rationale 
The rarity of MANECs, their clinical and biological heterogeneity, the limitation of 
diagnostic methods, the lack of awareness by researchers, and the lack of uniformity 
of the available evidence, implicate that a universal shared clinical approach to these 
neoplasms has not been codified yet. Therefore the real epidemiology and prognosis 
is not yet precisely known. It is noteworthy that nowadays the median OS of  
affected  patients  at any disease stage (or disease stage not specified) varies  greatly 
across the  retrospective series ranging between 10 and 78 months(30, 36, 47).	  So far, 
in clinical practice, aggressiveness and prognosis of both components drive the 
treatment choice even if it is not yet known if this type of approach is the most 
correct.  
Therefore, identifying effective therapeutic strategies for MANECs represents an 
unmet medical need and a major challenge.  
Based on the controversial terminology it should be highlighted that in this 
dissertation the author will use the term MANEC to refer to high grade mixed 
neuroendocrine-non-neuroendocrine carcinomas of the digestive tract as per the 
2010 WHO classification(1). 
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2.b Study design 
This is an Italian, multicenter, two-step, study, to retrospectively (step I) investigate 
the clinical and biological features of the patients with MANECs of the gastro-
entero-pancreatic (GEP) tract treated with chemotherapy, and then to prospectively 
(step II) define the activity and tolerance of two different chemotherapy regimens: 
- Arm A: NEC-oriented chemotherapy 
- Arm B: non-NEC-oriented chemotherapy 
 
Figure 3. Study design 
 
The study has been designed in two steps because of the rarity and heterogeneity of 
MANECs.  
Step II is dependent on the results of the retrospective part (step I) which is the real 
objective of this dissertation.  
The step II is planned to be a phase II, 2-arm, multicentre trial aiming to evaluate the 
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activity and toxicity of 2 regimens of therapies, NEC-oriented and non NEC-oriented 
as above mentioned, in patients with GEP-MANECs. As a biological point of view 
morphology and Ki67 of the NEC and non NEC and also somatostatin receptors 2A 
(SSTR2A) using specific antibodies, mismatch repair protein (MMR) deficiency, 
will be evaluated. Then, as exploratory analyses, data concerning mutations of RAS, 
BRAF, TP53 will be detect by PCR pyrosequencing(48) and Next Generation 
Sequencing (NGS)(49). 
 
3. Material and methods  
3.a Search strategy  
A comprehensive literature search was designed and conducted by an experienced 
professional medical librarian (W.R.) with input from the study investigators. We 
searched the electronic databases Ovid MEDLINE, Embase, Scopus and the 
Cochrane Library. Various combinations of database-specific controlled vocabulary 
(subject headings) were used, supplemented by keywords, title and abstract terms for 
the concepts and synonyms relating to MANEC, mixed adenoneuroendocrine 
carcinoma, MiNEN and mixed neuroendocrine-non-neuroendocrine neoplasms. 
Bibliographies of relevant papers were examined and citing articles were identified 
using Clarivate Web of Science. Populations searched were limited to Western 
Countries. Language was restricted to English, and no date restrictions were applied. 
The full search strategies employed are reported in the Appendix. 
The investigators identified papers eligible for further review by examination of 
abstracts and titles. If a paper was deemed relevant, the full-text version was 
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obtained and reviewed, applying the appropriate inclusion and exclusion criteria 
(Fig. 4a, 4b, 4c) (Appendix). 
Selection criteria 
Clinical and pathological reviews and retrospective papers on mixed neuroendocrine 
and non-neuroendocrine tumours conducted over the last fifty years were included. 
Any systemic antitumour therapy and treatment line was admitted. Case reports and 
case series with less than 10 patients were excluded. Congress abstracts were 
excluded as well.  
Two independent authors (F.S. and M.M.) assessed the eligibility of publications.  
 
3.b Case selection and sample size 
Case selection 
The clinical case selection of this retrospective study started from the same 
pathological sample size of a recent previous analysis on 160 surgical samples 
already published by Milione et al.(28) of which this work is the corresponding 
clinical retrospective conclusion. 
At beginning the surgical pathology and clinical databases of eleven Italian 
institutions were retrospectively searched between 1995 and 2016, and patients with 
one of the following diagnoses at histology report sign-out were selected: ‘mixed 
exocrine-neuroendocrine carcinoma’, ‘adenoneuroendocrine carcinoma (MANEC)’, 
‘composite glandular endocrine carcinoma’, ‘carcinoma with neuroendocrine 
differentiation’, ‘amphicrine/combined, carcinoma or tumour’, ‘mixed 
adenocarcinoma and neuroendocrine carcinoma’. Exclusion criteria were (i) cases 
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with only biopsy material available; (ii) cases with either NEC or non-NEC 
component <30%; (iii) cases in which the neuroendocrine component was well 
differentiated (24). 
Sample size 
At the beginning a total of 200 candidate cases were identified. Thereafter the case 
selection established the MANEC diagnosis pathological confirmation. Therefore, 
the patients’ charts and tumour morphology were carefully revised, first by the 
pathologist of the case-proposing hospital and then by a panel of seven expert 
pathologists (M.M., A.P., P.S., A.V., L.A., S.L.R. and C.C.) using a multihead 
microscope. During panel consensus meetings, the original diagnosis was reviewed 
and further workup was carried out whenever panelists disagreed or quantitative 
evaluations approached cut-off values. For qualitative parameters a majority decision 
was adopted, while for quantitative evaluations, the mean of values obtained by the 
individual panelists was taken as final. MANEC identification, quantitative 
evaluation of the NEC vs non-NEC components and subtype characterization as 
collision or combined were based on parallel investigation of at least two consecutive 
sections from representative blocks, stained with hematoxylin-eosin and 
synaptophysin, respectively. Ki67 proliferative rate (or other histochemical 
parameters investigated) was assessed on a third consecutive section. The 
identification of an amphicrine component was based on finding synaptophysin 
reactivity within the cytoplasm of cells also showing signet ring or gland-forming 
patterns after alcian blue counterstaining of the same section or with the help of an 
adjacent section stained with PAS and alcian blue. At the end, 160 tissue samples 
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met all the above criteria and were used to start the clinical selection.  
The clinical data collection required a rigorous retrospective search among the 
clinical databases of those eleven Italian institutions.  It was performed between 
2016 and 2018 and it has been coordinated by a clinical researcher (F. S.), deeply 
involved in neuroendocrine clinical and research activity. Clinical inclusion criteria 
were: (i) MANEC diagnosis according with 2010 WHO classification; (ii)  primary 
site from the gastro-entero-pancreatic (GEP) tract; (iii) patients underwent primary 
site surgery; (iv) availability of follow up information. Goblet cells neoplasms were 
not included. Other relevant clinical information were: (i) functional status (SSTR2A 
expression and FDG uptake status) at diagnosis (surgery); (ii) stage at diagnosis 
(locally advanced or metastatic); (iii) metastases timing (synchronous or 
metachronous); (iv) timing of chemotherapy received (adjuvant, pre-operative, 
perioperative, palliative); (v) type of chemotherapy received (regimen); (vi) toxicity; 
(vii) biochemical expression of specific markers (CEA, CA 19.9, NSE). 
The main barriers into collecting clinical data were: (i) second pathological opinions 
without clear clinical information; (ii) second clinical opinions without clear follow 
up information; (iii) incomplete clinical traceability due to the lack of recording tools 
in the analysed period. 
At the end, among the 160 patients with pathological centralised diagnosis of GEP-
MANEC above mentioned, 51 patients met all the above clinical criteria and were 
enrolled in the study: (i) 27 from Istituto Nazionale dei Tumori IRCCS (Milano); (ii) 
7 from Istituto Clinico Humanitas IRCCS (Rozzano, Milano); (iii) 11 from Ospedale 
di Circolo (Varese); (iv) 6 from Istituto Europeo di Oncologia IRCCS (Milano). 
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An expert pathologist (M.M.), already involved in the previous pathological study, 
reviewed again the 51 surgical samples to confirm biological features and 
homogenize the approach. 
Since this study is part of a specific research line in which the clinical work 
represents the consequent conclusion of the previous pathological analysis(28) it has 
been assumed that the Ethical Committee of Fondazione IRCCS Istituto Nazionale 
dei Tumori (Milan, Italy) approval (n° INT 21/16) still counted including the present 
clinical study that was performed according to the clinical standards of the 1975 and 
1983 Declaration of Helsinki. 
 
3.c Histologic and immunohistochemical analyses (Fig. 5A, 5B) 
 
Figure 5A, 5B. MANEC, Immunohistochemical definition. 
 
Morphologic analysis considered: (a) assessment of the percentage of NEC and non-
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NEC components; (b) morphology of non-NEC component: adenoma, 
adenocarcinoma, mucinous carcinoma, signet ring carcinoma, squamous cell 
carcinoma and acinar cell carcinoma (only in pancreatic site)(24); (c) morphology of 
NEC component: small cell or large cell according to WHO 2010(1); (d) necrosis in 
the NEC component; (e) Ki67 index was defined using the MIB antibody as a 
percentage of 500–2000 cells counted in areas of strongest nuclear labeling (‘hot 
spots’)(50); (f) mitotic count (MC) was evaluated in at least 10 HPF (10 HPF = 2 
mm2)(50); (g) quantitative assessment of NEC, non-NEC or mixed type components 
in lymph node metastases and/or in distant metastases; (h) tumour staging according 
to the Union for International Cancer Control/American Joint Committee on Cancer 
(UICC/AJCC) 8th edition(51); (i) lymphovascular invasion (evaluated on both 
hematoxylin-eosin (H&E) and/or CD31-stained sections); (l) perineural invasion; 
(m) intra and/or peritumoural lymphocytic infiltration; (n) prevalent tumour 
component (NEC, non-NEC or mixed type) on the deep invasive front; (o) type of 
combination of the NEC and non-NEC component: ‘collision’ when the two 
components were clearly demarcated, ‘combined’ when they were intimately 
admixed and ‘amphicrine/combined’, when the same cells displayed both 
neuroendocrine and non-neuroendocrine phenotype (as a rule this was observed in a 
combined histological background and (p) tumour budding defined according to the 
International Tumor Budding Consensus Conference 2016 (ITBCC)(52).  
The histochemical and immunohistochemical (IHC) study included: (a) Alcian Blue-
Periodic Acid-Schiff (PAS) to better define mucin production in the non-NEC 
epithelial neoplastic component; (b) synaptophysin and chromogranin-A (general 
neuroendocrine immunomarkers) in order to confirm the presence and extent of the 
	   23	  
NEC component (Fig. 1B); (c) Ki67 staining evaluated in both NEC and non- NEC 
components (1); (d) IHC assessment and evaluation in both components of several 
markers including p53, mismatch repair (MMR) proteins, and somatostatin receptor 
2A (SSTR2A) using specific antibodies.  
p53 was considered positive when ≥30% of cells were positive(53); SSTR2A was 
assessed according to Volante et al. (positive: 2+, 3+; negative: 0, 1+ score) (54). 
MMR deficiency was established according to the criteria reported by Chiaravalli et 
al.(55).  
   
3.d Biomolecular analysis 
Data concerning mutations of KRAS (codons 12 and 13), BRAF (codon 600), and 
TP53 (exons 5–8) were extracted from investigations performed for therapy decision 
making, either by PCR pyrosequencing (56) or by next-generation sequencing 
analysis (NGS) (49).  
 
4.e Statistical analysis  
Data were analysed by descriptive statistics. Differences in frequencies were 
assessed with the chi-square or the Fisher exact test. The primary study endpoint was 
the correlation of OS with primary tumour site, tumour stage, NEC subtype (large or 
small cell), non-NEC histotype, MANEC type (collision, combined, 
amphicrine/combined), percentage of NEC and non-NEC components (evaluated on: 
whole neoplasm, invasive front, lymph nodes and/or distant metastases), 
lymphocytic intratumoural and peritumoural infiltrate, angioinvasion, perineural 
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invasion and necrosis in the NEC component. The following parameters were 
separately evaluated in NEC and non-NEC components: MC, Ki67, MMR 
deficiency, p53 and SSTR2A. 
Overall survival was assessed from the time of diagnosis to the time of death or last 
follow-up. Survival curves were drawn according to the Kaplan–Meier method, and 
difference between groups was assessed with the log rank test. The proportions of 
patients surviving at different time points are presented with respective 95% CI. 
Univariable and multivariable Cox proportional hazards regression analysis was used 
to assess the prognostic significance of various clinical and histopathologic 
characteristics. Data analysis was performed using the SAS software (version 9.4, 
Cary, NC, USA). All tests were two sided and P values <0.05 were considered 
statistically significant. 
4. Results 
4.a Selected studies 
The systematic search initially identified 631 articles (Medline: 219 papers; Embase 
187 papers; Scopus 225) published between January 1st 1974 and August 1st 2018. 
The PRISMA flow diagram (Fig. 4) shows the article selection process. At the end of 
the research, 24 papers on GEP-MANECs were finally analysed and used as 
background of this analysis. Publications types included reviews (n = 15) 
(2-4, 6, 7, 13, 15, 23, 24, 31, 35-37, 57, 58), retrospective studies (n = 8)(10, 11, 16, 
18, 28, 59-61), and basic/translational research (n = 1)(27). 
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Figure 4. PRISMA flow diagram. Flowchart of study selection process. 
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4.b Patients features 
The main clinicopathologic features of the 51 patients enrolled in the retrospective 
step of this study are summarized in the Table 1. The series comprised MANECs 
from 3 main primary sites: colorectal (n = 32, 63%), with a prevalence in the right 
colon (23 cases) vs. the left colon (2 cases) and rectum (7 cases), followed by 
gastroesophageal (n = 14, 27%) locations, with a prevalence (9 cases) for stomach 
vs. gastro-esophageal junction (3 cases) and esophageal tumours (1 case). This group 
did include also 1 duodenal case. Pancreatobiliary locations were the least common 
(n = 5, 10%), the majority of these were pancreatic tumours (4 cases) compared to 
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Ampulla of Vater (1 case). No MANECs were found in the small bowel. The series 
comprised mainly patients 60-69 years old (n = 20, 39%) with colorectal MANECs 
among all the age ranges evaluated (< 60 years old; 60-69; 70+). There were more 
males than females (62% vs 37%), and this difference was maintained across tumour 
sites although not statistically significant (P = 0.61). Most neoplasms (74%) were 
locally advanced (n = 38, 74.5%) at diagnosis (surgery) in all the 3 groups of 
patients. Among the 51 evaluable patients 36 (71%) developed metastases: (i) 12 
(24%) synchronous, (ii) 24 (47%) metachronous; liver alone (n = 17, 33%) was the 
most frequent metastatic site. Metabolic imaging by 18-FDG PET/CT was done only 
in about one third of the whole  population (n = 14, 27%) (Table 1).  
Most MANECs (n = 37, 72%) had a NEC component > 50% (Table 1) and the large 
cell type (n = 28, 55%) was more frequent compared to the small or intermediate cell 
type. Thirty-one (61%) tumours showed a ‘combined’ pattern, 11 (22%) a purely 
‘amphicrine’ pattern, and 9 (18%) a ‘collision’ pattern (Table 1). 
In the non-neuroendocrine component the conventional adenocarcinoma was the 
dominant histotype (n = 29, 57%) (Table 1). 
Angioinvasion was seen in all MANEC cases. Neoplastic emboli in vessels were 
prevalently of NEC or mixed NEC/non-NEC type. Nodal metastases were of pure 
NEC histotype in 9 (18%) and mixed NEC/non-NEC in 36 (71%) cases. In distant 
metastases, pure NEC histology was found in 5 (10%) cases, and mixed NEC/non-
NEC histology in 2 cases (4%). Pure non-NEC component was not detected in 
metastases (Table 1).  
Focusing only on the NEC component of the 51 MANECs, the proliferation index 
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evaluated with Ki67 was < 55% in 13 (25.5%) patients, like the so called type B 
NEC entity (32), and > 55% in 38 (74.5%) as the type C NEC entity(30). Then, while 
the mitoses [evaluated by mitotic index (MI)], in the neuroendocrine component 
were mostly in a intermediate range (30-49) (n = 21, 41%), in the non-
neuroendocrine component they were predominantly (n = 23, 45%) in a lower range 
(0-29). 
Biochemical tumour markers more used in the clinical management of non-
neuroendocrine carcinomas which are the carcinoembryonic antigen (CEA) and the 
carbohydrated antigen 19. 9 (CA 19.9), and the marker more often used in clinical 
practice in the monitoring of high grade neuroendocrine neoplasms which is the 
neurono-specific antigen (NSE), were evaluated in available patients. Among them, 
NSE more than 5 ng/mL (normal < 15 ng/mL) was statistically significant (P = 
0.003). 
Biomolecular analysis were performed in 43 (84%) patients in the overall population 
and specific mutations of KRAS, BRAF, and TP53 were observed in 22 (43%) 
patients (Table 1).  
Table 1.  Main characteristics of patients with MANEC according to tumour 
site 	  
	   All	   Colorectal	   Gastroesophageal	   Pancreatobiliary	   P-­‐value	  
	   N	  (%)	   N	   N	   N	   	  
All	   51	  (100)	   32	   14	   5	   	  
Center	   	   	   	   	   	  Milan,	  INT	   27	  (52.9)	   21	   4	   2	   	  Milan,	  Humanitas	   7	  (13.7)	   3	   2	   2	   	  Varese	   11	  (21.6)	   6	   5	   .	   	  Milan,	  IEO	   6	  (11.8)	   2	   3	   1	   0.065	  
Age	  at	  diagnosis	   	   	   	   	   	  <60	   16	  (31.4)	   9	   5	   2	   	  60-­‐69	   20	  (39.2)	   12	   5	   3	   	  70+	   15	  (29.4)	   11	   4	   .	   0.66	  
Year	  of	  surgery	   	   	   	   	   	  2000-­‐2004	   11	  (21.6)	   7	   3	   1	   	  2005-­‐2009	   7	  (13.7)	   3	   4	   .	   	  2010-­‐2014	   22	  (43.1)	   15	   4	   3	   	  2015-­‐2016	   11	  (21.6)	   7	   3	   1	   0.68	  
Gender	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Male	   32	  (62.7)	   21	   9	   2	   	  Female	   19	  (37.3)	   11	   5	   3	   0.61	  
Stage	  at	  diagnosis	   	   	   	   	   	  Locally	  advanced	   38	  (74.5)	   22	   11	   5	   	  Metastatic	   13	  (25.5)	   10	   3	   .	   0.38	  
Metastases	   	   	   	   	   	  Sinchronous	   12	  (23.5)	   9	   3	   .	   	  Metachronous	   24	  (47.1)	   14	   5	   5	   	  Non	  metastatic	   15	  (29.4)	   9	   6	   .	   0.19	  
Site	  of	  metastasis	   	   	   	   	   	  Hepatic	   17	  (33.3)	   12	   4	   1	   	  Extra-­‐hepatic	   12	  (23.5)	   8	   2	   2	   	  Hepatic	  +	  extra-­‐hepatic	   6	  (11.8)	   3	   2	   1	   	  n/a	   1	  (2)	   .	   .	   1	   0.39	  
68-­‐Gallium	  PET/CT	  
/Octreoscan® 	  	   	  
	   	   	   	  Not	  done	   30	  (58.8)	   20	   7	   3	   	  Positive	   4	  (7.8)	   2	   1	   1	   	  Negative	   2	  (3.9)	   1	   .	   1	   0.39	  
18-­‐FDG	  PET/CT	  	   	   	   	   	   	  n/a	   13	  (25.5)	   7	   6	   .	   	  Not	  done	   24	  (47.1)	   15	   5	   4	   	  Positive	   12	  (23.5)	   8	   3	   1	   	  Negative	   2	  (3.9)	   2	   .	   .	   1.00	  
Pre-­‐operative	  therapy	   	   	   	   	   	  No	   40	  (78.4)	   26	   9	   5	   	  Yes	   11	  (21.6)	   6	   5	   .	   0.21	  
CBDCA+VP16+Radiotherapy	   2	  (3.9)	   2	   .	   .	   	  
CDDP+5-­‐FU	   1	  (2)	   .	   1	   .	   	  
CT	  +	  RT	   1	  (2)	   1	   .	   .	   	  
ECF	   1	  (2)	   .	   1	   .	   	  
FOLFOX	   2	  (3.9)	   1	   1	   .	   	  
FOLFOX4+AVASTIN	   1	  (2)	   1	   .	   .	   	  
GEMOX	   1	  (2)	   .	   1	   .	   	  
XELOX	   2	  (3.9)	   1	   1	   .	   	  
Best	  response	   	   	   	   	   	  
CR	   1	  (2)	   .	   1	   .	   	  
PR	   4	  (7.8)	   3	   1	   .	   	  
SD	   4	  (7.8)	   2	   2	   .	   	  
PD	   1	  (2)	   .	   1	   .	   	  
Too	  early	   1	  (2)	   1	   .	   .	   0.77	  
	  
Adjuvant	  therapy	   	  
	   	   	   	  
	   	   	   	   	   	  No	   37	  (72.5)	   25	   8	   4	   	  Yes	   14	  (27.5)	   7	   6	   1	   0.32	  
Regimen	   	   	   	   	   	  
CF	   1	  (2)	   .	   1	   .	   	  
CRT:	  FOLFOX+RT	   1	  (2)	   1	   .	   .	   	  
EAP+SSA	   1	  (2)	   .	   1	   .	   	  
FOLFOX	   3	  (5.9)	   1	   1	   1	   	  
FOLFOX4	   1	  (2)	   1	   .	   .	   	  
FU/FA	   1	  (2)	   .	   1	   .	   	  
GEMOX	   1	  (2)	   .	   1	   .	   	  
XELOX	   4	  (7.8)	   3	   1	   .	   	  
XELODA	   1	  (2)	   1	   .	   .	   0.76	  
Relapse	   	   	   	   	   	  No	   23	  (45.1)	   17	   6	   .	   	  Yes	   28	  (54.9)	   15	   8	   5	   0.09	  
First	  line	  treatment	  (metastatic)	   	   	   	   	   	  No	   28	  (54.9)	   19	   8	   1	   	  Yes	   23	  (45.1)	   13	   6	   4	   0.27	  
Number	  of	  cycles	   	   	   	   	   	  1-­‐2	   10	  (19.6)	   6	   2	   2	   	  3-­‐5	   5	  (9.8)	   4	   1	   .	   	  6+	   8	  (15.7)	   3	   3	   2	   0.69	  
Best	  response	   	   	   	   	   	  PR	   3	  (5.9)	   1	   1	   1	   	  SD	   4	  (7.8)	   2	   1	   1	   	  PD	   15	  (29.4)	   9	   4	   2	   	  Too	  Early	   1	  (2)	   1	   .	   .	   0.97	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2nd	  line	  treatment	  (metastatic)	   	   	   	   	   	  No	   16	  (31.4)	   9	   5	   2	   	  Yes	   7	  (13.7)	   4	   1	   2	   0.70	  
Number	  of	  cycles	   	   	   	   	   	  1-­‐2	   3	  (5.9)	   2	   1	   .	   	  6+	   4	  (7.8)	   2	   .	   2	   0.43	  
Best	  response	   	   	   	   	   	  SD	   3	  (5.9)	   1	   .	   2	   	  PD	   4	  (7.8)	   3	   1	   .	   0.26	  
3rd	  line	  treatment	  (metastatic)	   	   	   	   	   	  No	   5	  (9.8)	   2	   1	   2	   	  Yes	   2	  (3.9)	   2	   .	   .	   0.62	  
Number	  of	  cycles	   	   	   	   	   	  1-­‐2	   2	  (3.9)	   2	   .	   .	   	  
Best	  response	   	   	   	   	   	  SD	   1	  (2)	   1	   .	   .	   	  PD	   1	  (2)	   1	   .	   .	   	  
CEA	   	   	   	   	   	  <2	   10	  (19.6)	   8	   1	   1	   	  2	   17	  (33.3)	   8	   7	   2	   	  3	   10	  (19.6)	   6	   4	   .	   	  4	  +	   14	  (27.5)	   10	   2	   2	   0.38	  
CA	  19.9	   	   	   	   	   	  <3	   17	  (33.3)	   8	   7	   2	   	  3-­‐9	   23	  (45.1)	   16	   5	   2	   	  10+	   11	  (21.6)	   8	   2	   1	   0.56	  
NSE	   	   	   	   	   	  <3	   9	  (17.6)	   4	   3	   2	   	  3	   16	  (31.4)	   8	   8	   .	   	  4	   16	  (31.4)	   15	   .	   1	   0.003	  5	  +	   10	  (19.6)	   5	   3	   2	   Trend	  0.23	  
Ki67	  NEC	   	   	   	   	   	  <55%	   13	  (25.5)	   7	   4	   2	   	  ≥55%	   38	  (74.5)	   25	   10	   3	   0.70	  
Ki67	  non-­‐NEC	   	   	   	   	   	  <55%	   20	  (39.2)	   13	   4	   3	   	  ≥55%	   31	  (60.8)	   19	   10	   2	   0.51	  
%	  NEC	  component	   	   	   	   	   	  <50%	   14	  (27.5)	   10	   3	   1	   	  ≥50%	   37	  (72.5)	   22	   11	   4	   0.89	  
%	  non-­‐NEC	  component	   	   	   	   	   	  <50%	   26	  (51)	   15	   8	   3	   	  ≥50%	   25	  (49)	   17	   6	   2	   0.76	  
NGS	   	   	   	   	   	  Not	  performed	   8	  (15.7)	   5	   3	   .	   	  Wild	  type	   21	  (41.2)	   10	   6	   5	   	  KRas+	  Nras	   5	  (9.8)	   4	   1	   .	   	  BRAF	   1	  (2)	   1	   .	   .	   	  TP53	   13	  (25.5)	   10	   3	   .	   	  Kras	   3	  (5.9)	   2	   1	   .	   0.63	  
Stage	   	   	   	   	   	  IIB	   1	  (2)	   1	   .	   .	   	  IIIA	   4	  (7.8)	   3	   1	   .	   	  IIIB	   35	  (68.6)	   19	   11	   5	   	  IV	   11	  (21.6)	   9	   2	   .	   0.56	  
%	  NEC	  LYMPHNODE	  METASTASES	   	   	   	   	   	  <100%	  (Mixed)	   36	  (70.6)	   20	   12	   4	   	  100%	  (Pure	  NEC)	   9	  (17.7)	   7	   1	   1	   	  N0	   6	  (11.8)	   5	   1	   .	   0.53	  
%	  NEC	  DISTANT	  METASTASES	   	   	   	   	   	  <100%	  (Mixed)	   2	  (3.9)	   1	   0	   1	   	  100%	  (Pure	  NEC)	   5	  (9.8)	   3	   4	   1	   	  M0	   44	  (86.3)	   27	   13	   4	   0.43	  
p53	  NEC	   	   	   	   	   	  n/a	   1	  (2)	   1	   .	   .	   	  0	   16	  (31.4)	   12	   2	   2	   	  <50	   10	  (19.6)	   5	   4	   1	   	  ≥50	   24	  (47.1)	   14	   8	   2	   0.49	  
P53	  non-­‐NEC	   	   	   	   	   	  n/a	   1	  (2)	   1	   .	   .	   	  0	   26	  (51)	   18	   5	   3	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<50	   19	  (37.3)	   10	   7	   2	   	  ≥50	   5	  (9.8)	   3	   2	   .	   0.66	  
MMR	   	   	   	   	   	  Not	  stable	   2	  (3.9)	   1	   1	   .	   	  Stable	   49	  (96.1)	   31	   13	   5	   0.62	  
NEC	  MITOSIS	   	   	   	   	   	  0-­‐29	   15	  (29.4)	   8	   4	   3	   	  30-­‐49	   21	  (41.2)	   15	   5	   1	   	  50+	   15	  (29.4)	   9	   5	   1	   0.63	  
Non-­‐NEC	  MITOSIS	   	   	   	   	   	  0-­‐29	   23	  (45.1)	   13	   7	   3	   	  30-­‐49	   16	  (31.4)	   9	   6	   1	   	  50+	   12	  (23.5)	   10	   1	   1	   0.42	  
TYPE	  OF	  MANEC	   	   	   	   	   	  Small	  cells	   11	  (21.6)	   7	   2	   2	   	  Large	  cells	   28	  (54.9)	   17	   10	   1	   	  Intermediate	  cells	   12	  (23.5)	   8	   2	   2	   0.36	  
TYPE	  OF	  NON-­‐MANEC	   	   	   	   	   	  Adenoma	   4	  (7.8)	   4	   .	   .	   	  Adenocarcinoma	  NAS	   29	  (56.9)	   16	   9	   4	   	  Squamous	  Carcinoma	   3	  (5.9)	   2	   1	   .	   	  Acinic	  Carcinoma	   1	  (2)	   .	   .	   1	   	  Mucinous	  Carcinoma	   6	  (11.8)	   4	   2	   .	   	  Signet	  Ring	  Carcinoma	   2	  (3.9)	   1	   1	   .	   	  Amphicrin	  Carcinoma	   4	  (7.8)	   4	   .	   .	   	  Adenosquamous	   2	  (3.9)	   1	   1	   .	   0.58	  
BUDDING	   	   	   	   	   	  Absent	   5	  (9.8)	   1	   4	   .	   	  Mild	   12	  (23.5)	   10	   1	   1	   	  Moderate	   13	  (25.5)	   8	   4	   1	   	  Severe	   21	  (41.2)	   13	   5	   3	   0.15	  
SSTR2A	   	   	   	   	   	  Negative	   27	  (52.9)	   16	   10	   1	   	  Positive	  1+	   9	  (17.6)	   7	   2	   .	   	  Positive	  2+	   9	  (17.6)	   6	   1	   2	   	  Positive	  3+	   6	  (11.8)	   3	   1	   2	   0.18	  
Peritumoural	  infiltration	   	   	   	   	   	  Absent	   15	  (29.4)	   9	   4	   2	   	  Mild	   25	  (49)	   14	   8	   3	   	  Moderate	   11	  (21.6)	   9	   2	   .	   0.72	  
Intratumoural	  infiltration	   	   	   	   	   	  Absent	   20	  (39.2)	   11	   6	   3	   	  Mild	   28	  (54.9)	   20	   6	   2	   	  Moderate	   3	  (5.9)	   1	   2	   .	   0.38	  
HISTOTYPE	  INVASIVE	  TUMOUR	  
FRONT	   	   	   	   	   	  Non-­‐NEC	   3	  (5.9)	   1	   1	   1	   	  NEC	   17	  (33.3)	   12	   4	   1	   	  Non-­‐NEC+NEC	   31	  (60.8)	   19	   9	   3	   0.56	  
Type	  of	  MANEC	   	   	   	   	   	  Collision	   9	  (17.6)	   7	   1	   1	   	  Combined	   31	  (60.8)	   17	   11	   3	   	  Amphicrin	   11	  (21.6)	   8	   2	   1	   0.60	  
	  
Legend:	   n/a:	   not	   available;	   CBDCA:	   carboplatin;	   CDDP:	   cisplatin;	   CT:	   chemotherapy	   not	   otherwise	  specified;	   ECF:	   epirubicin+cisplatin+5-­‐fluorouracil;	   FOLFOX:	   5-­‐fluorouracil+leucovorin+oxaliplatin;	  
GEMOX:	   gemcitabine+oxaliplatin;	   CR:	   complete	   response;	   PR:	   partial	   response;	   SD:	   stable	  disease;	   PD:	  progression	   disease;	   CF:	   cisplatin+5-­‐fluorouracil;	   SSA:	   somatostatin	   analogs;	   FU/FA:	   5-­‐fluorouracil+leucovorin;	   NGS:	   next	   generation	   sequencing;	   MMR:	   mismatch	   repair	   protein;	   SSTR2A:	  somatostatin	   receptor	   type	   2A;	   MANEC: mixed adenoneuroendocrine carcinomas; NEC: 
neuroendocrine carcinoma.  
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4.c Clinical outcomes 
Locally advanced stage 
Eleven patients (22%) underwent pre-operative therapy (5 with NEC-oriented 
regimens and 7 with non-NEC oriented regimen), 14 (27%) adjuvant (only one with 
a NEC-oriented regimen), and 6 (12%) perioperative chemotherapy (Table 1). In the 
first group the authors observed 4 (8%) partial responses (PR), 4 (8%) stable disease 
(SD), one (2%) progression of disease (PD). Eight out of 14 (57%) patients who 
underwent adjuvant chemotherapy, and 3/6 who received both pre-operative and 
adjuvant chemotherapy, relapsed.  
Metastatic stage  
Twenty-three patients (45%) (some metastatic at diagnosis and some relapsed after 
adjuvant therapy) received first line therapy with a median of 1-2 cycles in 20% 
patients, 3-5 in 10%, and more than 61 in 6%. Thirteen patients received 
fluoropyrimidines/oxaliplatin (57%), 1/23 (4%) peptide receptor radionuclide 
therapy), radiotherapy plus or minus combined with paclitaxel 2/23 (9%), 
capecitabine/temozolomide 1/23 (4%), cetuximab or bevacizumab as monotherapy 
2/23 (9%), fluoropyrimidines/irinotecan 1/23 (4%), gemcitabine 2/23 (9%), and 1/23 
(4%) metronomic capecitabine. The overall response rate (ORR = CR+PR+SD) of 
the global population after first line therapy was 14%. Fifteen out of 23 (30%) 
patients had PD (Table 1).  
Only 7 patients underwent a second line therapy: 1/7 (14%) cisplatin/5-fluorouracil, 
1/7 (14%) fluoropyrimidines/oxaliplatin, 1/7 (14%) PRRT, 1 (14%) 
irinotecan/cetuximab, 3/7 (43%) not known. There were 6% SD, and 4 (8%) PD. 
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4.d Survival analysis 
Systemic therapy 
In the whole cohort, the median OS was 1.2 years (95% CI 0.8-1.6) (Fig. 6A Overall 
survival), 1.6 years for patients who underwent adjuvant therapy (P = 0.20), 1.0 year 
for those who received neo-adjuvant therapy, 2.9 years for those who received peri-
operative therapy (P = 0.46), and 0.9 years for patients who received first line 
therapy (Fig. 6D, C, B). 
 
 
Legend: Overall survival of the whole 51 GEP-MANECs population (A), of GEP-MANECs during 
first line therapy (B) or peri-operative therapy (C) or adjuvant therapy (D); Neo/adj: refers to 
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preoperative/adjuvant therapy. 
 
Proliferation 
A preliminary evaluation of the NEC component showed 55% to be an optimal 
prognostic cut-off for Ki67 index (Fig.7A) and it was ≥55% in the large majority 
(74.5%) of cases. On the other hand, in the non-NEC component, Ki67 was ≥55% in 
61% of cases (Fig.7B). 
Patients with Ki67 index <55% in the NEC component (median 2.9 years; 95% CI 
2.4-3.4) had a significatively longer OS than those with Ki67 ≥ 55% (median 1.0; 
95% CI 0.7-1.2) (P = 0.0004). The latter showed a hazard ratio (HR) of 3.61 (95% 
CI 1.69–7.72) vs Ki67 < 55% (P = 0.0009) after adjustment for tumour site, which 
retained high significance at multivariable analysis (Fig. 7A and Table 2).  
Patients with mitotic count (MC) >50 mitoses/10 HPF vs <50 mitoses/10 HPF had 
hazard ratio (HR) of 1.81 (95% CI 0.96–3.44) (P = 0.07) after adjustment for tumour 
site but they revealed high significance at multivariable analysis (Table 2). 
In the non-NEC component, patients with Ki67 index <55% (median 1.2 year 
months; 95% CI 0.8-3.4) had a slightly longer OS than those with Ki67 ≥ 55% 
(median 1.1; 95% CI 0.8-1.5) although not significantly (P = 0.17) (Fig. 7B). 
Moreover a Ki67 index of ≥55% was associated with a tumour site-adjusted HR of 
1.42; 95% CI 0.75–2.71 (P = 0.29) vs <55%, while a MC ≥ 50/10 HPF lacked any 
significant difference compared to MC<50/10 HPF (Table 2). 
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Figure 7 A (left), B (right) 
 
Primary tumour site 
Overall survival according to Ki67 in the NEC counterpart was shorter in patients 
with colorectal tumours (median 1.1 years; 95% CI 0.6-1.5) compared to patients 
with tumours in other digestive system sites: gastroesophageal (median 1.2 years; 
95% CI 0.8-2.4) or pancreatobiliary (median 2.1 years; 95% CI 1.2-4.4) (Fig. 7 C, D 
and Table 2). The latter had a hazard ratio (HR) of 0.57 (95% CI 0.22–1.50) after 
adjustment for tumour site, which revealed high significance at multivariable 
analysis model3 (which retains only variables showing an association (P < 0.10) with 
OS) with a HR of 0.25 (0.08-0.83) (P = 0.02) (Fig. 7C, D and Table 2).  
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Fig. 7 C (left), D (right) 
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Legend: D117: tyrosine-protein kinase Kit; Ki67: Ki67 index; M+: Liver metastases; MANEC: 
Mixed adeno-neuroendocrine carcinoma; MC: Mitotic count; N+: Lymph node metastases; NEC: 
neuroendocrine carcinoma; NGS: Next Generation Sequencing; SSTR2: somatostatin receptor 2A.  
Multivariable model 1: includes all factors associated with overall survival after single adjustment 
for tumour site; 
Multivariable model 2: retains only variables showing an association (P<0.10) with overall survival. 
 
 
Immunohistochemistry markers  
The majority of IHC markers showed no statistical association with OS.  
Moreover in the NEC-component SSTR2 had a hazard ratio (HR) of 1.85 (95% CI 
1–3.42; P = 0.05) after adjustment for tumour site, which retained high significance 
at both multivariable analysis models: model2 (which includes all factors associated 
with OS after single adjustment for tumour site) with a HR of  2.83 (0.98-8.16) (P = 
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0.05), and model3 (which retains only variables showing an association (P < 0.10) 
with OS) with HR 3.45 (1.60-7.45) (P = 0.002) (Fig. 2A,B and Table 2).  
Loss of MMR proteins (MLH1 and PMS2 in all cases) was found in 2/51 neoplasms 
therefore no correlation with OS waspossible.  
Stage  
Patients with early-stage (I–IIIA) tumours (5 cases) had longer OS (median 2.5 
years; 95% CI 2.1-3.0) compared to 35 patients with stage IIIB (median 1.2 years; 
95% CI 0.8-1.6) or 11 patients with stage IV disease (median 1.0 years; 95% CI 0.3-
1.2), with a significant difference (P = 0.02) between I–IIIA and IIIB+IV cases (Fig. 
4E) in the neuroendocrine component. In the non-neuroendocrine component, 
patients with early-stage (II–III) tumour (40 cases) had longer OS (median 1.2 years; 
95% CI 0.9-2.4) compared to 11 patients with stage IV (median 1.0 years; 95% CI 
0.3-1.2), with a significant difference (P = 0.01) between II-III and IV cases (Fig. 
4F). 
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Fig. 7 E (left), F (right) 
When an analysis of OS adjusted for tumour site was performed, OS was shown to 
be significantly associated with tumour stage, MANEC subtype (mixed amphicrine/ 
combined vs collision), SSTR2 (positive vs negative), NGS gene mutations (mutated 
vs wild type), in addition to Ki67 in the NEC component (Table 2).  
Multivariable analysis  
At multivariable analysis, tumour site, stage, Ki67 and MC in the NEC component 
and SSTR2 were independently associated with OS (Table 2). Patients with 
pancreatobiliary tumours (HR = 0.15; 95% CI 0.08–0.83; P = 0.02) had significantly 
better survival compared to patients with other gastrointestinal (GI) MANECs. 
Patients with stage IV in the NEC component had a 16.5 fold increase risk of death 
(95% CI 3.09–88.2; P = 0.001) than those with stage I-IIIA and IIIB. 
Patients with Ki67 ≥ 55% in the NEC component had a 3.73 fold increased risk of 
death (95% CI 1.16–12; P = 0.03) compared to patients with a Ki67 < 55%, while 
patients with MC ≥ 50 mitoses/10 HPF had a 4.03 fold risk of death (95% CI 1.47–
11, P = 0.007). The tumours with SSTR2 positive had a 2.83 fold risk of death (0.98-
8.16) compared to those with SSTR2 negative (Table 2). 
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5. Discussion 
This study confirmed that GEP-MANECs are poor prognosis malignancies, 
heterogeneously managed. Weaknesses of our work are as follows: (i) proposed 
chemotherapy regimens were varied, including NEC-oriented and non-NEC-oriented 
ones, mainly based on the gut-feeling of the treating oncologists; (ii) retrospective 
design; (iii) lack of clinical information mainly due to the long period of time 
considered. It was really difficult collecting clinical data, considering that some 
patients had received chemotherapy outside the referral institute. 
Strengths are the following: surgical samples primary tumour series with a clear 
central pathology review by a team of NEN-dedicated expert pathologists(28); this 
latter is a critical point, often lacking in published studies, considering the rarity and 
debated definition of this entity;  relatively high number series, considering the poor 
quality of literature data and rarity of the disease. 
Mixed adeno-neuroendocrine carcinoma of the digestive system is a very rare 
tumour. Thus, most of the published studies concerning this disease entity are case 
reports. To the best of our knowledge, with exception of studies including also goblet 
cell carcinomas, the number of patients included in this analysis is in line with those 
of other clinical retrospective studies on GEP-MANECs from Western Countries 
over the last forty years, which ranged between 14 and 75 patients(58, 60).  
Moreover the anthropometric data of our patients are consistent with other reported 
cohorts of MANECs(34, 58, 60).  
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From a strategy-management point of view,  despite the small number of patients 
evaluated, in the locally advanced setting the approach to the patients of this analysis 
was quite different to that reported  in  other  studies(13, 37, 47, 58, 59, 61),  with  
curative  surgery  being  offered  to  nearly  two-thirds of the whole population and  
peri-operative treatment delivered only to a handful of resected cases.  
Moreover, in the present study, in patients with locally advanced disease,	   peri-­‐operative	   or	   adjuvant chemotherapy regimens were most commonly adherent to 
the clinical practice guidelines for pure adenocarcinomas from the same sites of 
origin; this might be explained by the lack of solid evidence advocating the use 
of adjuvant and/or peri-operative chemotherapy or chemo-radiotherapy for 
potentially curable pure NENs. Moreover the survival advantage for the patients who 
received adjuvant therapy (Fig. 1D) was most likely attributable to the better 
performance status at baseline compared to the untreated arm in which many patients 
died in the first months after surgery. 
So far, the right therapeutic strategy of  advanced GEP-MANECs has not yet been 
codified, therefore a universally shared clinical management is not known. 
Considering the biological aggressiveness of GEP-MANECs, chemotherapy could 
play a key role, but the choice of the type of chemotherapy still represents an unmet 
medical need. Some authors suggest that the therapeutic strategy should be based on 
the most aggressive neoplastic component(24, 31), but since the lack of validated 
evidence, at present this theory remains a proposal to be validated with a study 
specically design on that. Indeed the clinical management of GEP-MANECs in the 
“real world” setting is quite varied and does not always focused on most aggressive 
part of the disease. 
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In our series, considering the whole population, on one hand the NEC component 
was higher than 50% in quite the 72% while the non-NEC counterpart in the 49%, on 
the other hand the Ki67 was higher than 55% in the 74.5% of cases in the NEC 
component, and in the 61% in the non-NEC counterpart. Nevertheless in the present 
study a fluoropyrimidines/oxaliplatin regimen, clearly most oriented to treat an 
advanced GI cancer rather than a NEC, has been offered almost to the half of the 
metastatic group of patients evaluated as first line of therapy with only 6% SD as 
best response and 10.8 months OS.  
In line with the theory to treat the most aggressive component of GEP-MANECs, on 
one hand, considering the NEC component, it should be highlighted that the clinical 
behavior of NECs is similar to that of small-cell lung cancer (SCLC). Since SCLC is 
known to be responsive to cisplatin and etoposide, this combination has been the 
most widely used combination in extra-pulmonary NECs although, the literature 
evidence on this regimen are based on old studies conducted in mixed population and 
not designed to evaluate the efficacy of these regimens in NEC(62, 63). On the other 
hand, when considering the exocrine component, the typical first-line chemotherapy 
backbone comprises a fluoropyrimidine (intravenous 5-FU or oral capecitabine) used 
in various combinations and schedules depending on the site of primary tumours 
with irinotecan or oxaliplatin(64, 65) +/- anti-VEGF or anti-EGFR(64) in the case of 
colon cancer or gemcitabine in case of pancreatic cancer(66). 
In the current study the prognosis of GEP-MANECs is driven mostly by the NEC 
component with special reference to its Ki67 proliferative index like in the recent 
evidence from the Italian pathologists(28). These similar results could suggest that (i) 
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the real prognosis of GEP-MANECs could depend only on the biology of both 
components regardless the type of therapy or that (ii) the therapy administered really 
influenced the prognosis also in the previous pathological report(28). 
Indeed, as previously reported for pure NECs, patients with Ki-67 <55% were less 
responsive to platinum-based chemotherapy, but had a longer survival(29) and 
moreover that a Ki67 threshold of 55% identified two main different prognostic 
classes of MANECs with significant survival differences(30). Therefore, although 
comparing different studies, on one side the findings of this analysis seem to show 
that the OS of MANECs with Ki67 ≥ 55% is closely similar to that of the 
corresponding pure poorly differentiated GEP-NECs with Ki67 ≥ 55% (type C NECs 
according to Milione et al. 2017)(30), and, on the other side, that the GEP-MANECs 
with Ki67 < 55% of our series showed better survival (35 months) compared to that 
of 24.5 months of the pure NECs with 21-55% Ki67 (type B NECs according to 
Milione et al. 2017)(30). Moreover for KRAS mutations in our series, the significant 
correlation with OS (P = 0.0025) after adjusted for side at univariate analysis seems 
to suggest a join point(64) with the pure adenocarcinoma counterpart, at least as for 
colorectal primary site. Moreover, the significantly shorter OS observed in the 
patients with primary colorectal tumours seem to reflect previous data (59) and 
reinforce the hypothesis that presence of the NEC component at the invasive front of 
MANECs or in metastases, could explain their aggressiveness and drive their 
prognosis(28). And then, although in our study BRAF mutations have been detected 
only in one patient among those twenty-two evaluated, considering our findings in 
terms of OS in this group of patients, and that colorectal NECs frequently exhibit 
BRAF mutations and are associated with a poor prognosis (67), mutations of BRAF 
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and moreover of RAS and TP53, should be prospectively investigated in a more 
homogeneous population of GEP-MANECs.  
In our study, stage was one of the factors independently associated with OS (Table 
2). Indeed our patients with stage IV showed a higher increase risk of death  than 
thoose with stage I-IIIA and IIIB as happened for pure site corresponding 
carcinomas. Therefore, our data support the WHO recommendation of considering 
MANECs as ordinary carcinomas, providing evidence for the application of the 
relevant dedicated UICC/AJCC staging system(5, 8) in the pathological reports. 
In the real life practice of our study, the functional characterization of the disease in 
some cases (6 cases) led to the 111In-pentetreotide or OctreoScan® (SRS, 
somatostatin receptor scintigraphy) or 68-gallium PET/CT for the evaluation of 
somatostatin receptors, in other cases (14 cases, 12 with positive uptake) to the 18-
FDG PET/CT, based on the expertise of the clinicians. While the receptors 
evaluation lost sense in these type of aggressive tumours, the role of 18-FDG 
PET/CT could be taken into account. The prognostic role of 18-FDG PET/CT has 
been evaluated in a phase II trial including 98 patients with NEN enrolled after 
surgery and scheduled for various therapies(68). It showed that among 18-FDG 
PET/CT, Ki67, chromogranin A (CgA), and the presence of hepatic metastases, the 
only parameter that correlated with the prognosis was the positivity to 18-FDG 
PET/CT. In our analysis, although the small number of cases evaluated, the positive 
uptake of almost all cases evaluated could suggest at least to include this parameter 
as part of a specific clinical score in a prospective way in such aggressive tumours. 
As for biochemical markers, although the positive trend of the neuron-specific 
enolase (NSE) for patients with more than 5 ng/ml which is not useful unless it is 
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contextualized at exact time points, its real meaning should be prospectically 
evaluated with rigorous blood sampling at specific times within the clinical strategy 
(i.e. histological diagnosis, beginning of therapy, every morphological/functional 
evaluation, disease progression). 
Finally, the significant association of some molecular markers, including p53, and 
SSTR2 (Table 2), that we found in both NEC and non-NEC components, seems to 
suggest a possible common origin of the two MANEC components from a 
pluripotent cancer stem cell, which undergoes divergent differentiation, during 
tumour progression as observed in previous studies(2, 7, 24).  
Conclusion 
In conclusion, this study of a clinical series of GEP-MANECs, confirms that GEP-
MANECs are an aggressive disease in which the prognosis is mainly driven by the 
NEC component, in particular to its Ki67 proliferative index. Moreover since the 
confirmed biological heterogeneity of GEP-MANECs, their rareness, the many 
diagnostic difficulties, and the lack of a universally shared clinical approach, this 
study cannot suggest a therapeutic strategy for GEP-MANECs nor that 
chemotherapy really impacts on the prognosis but it could be useful as “hypothesis 
generating study”. Therefore the STEP II of this work could be the right tool for 
collecting clinical-pathological information on GEP-MANECs in a prospective way 
and treat these patients with a more homogenous clinical approach.  
Moreover this work highlights again that (i) an expert pathologist in this field should 
review all the diagnosis dubious for MANEC to confirm diagnosis and evaluate all 
the most important prognostic factors, that (ii) the GEP-MANECs should be 
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managed in accordance with a reference centre for NENs to clearly characterise the 
patient and the disease and to homogenise the clinical therapeutic approach, and 
finally that (iii) since the NEC component is confirmed as the most important driver 
influencing the prognosis of GEP-MANECs, the second step of this reasearch is 
warranted. Therefore a prospective trial in a more homogeneous and well selected 
populations of GEP-MANECs, including a centralised revision of pathological 
samples, should be performed to evaluate the clinical activity and toxicity of two 
different regimens of chemotherapy NEC-oriented and non-NEC oriented with a 
prospectic exploratory analysis of the main morphological, immunohistochemical, 
and biomolecular prognostic factors.   
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Appendix 
Search strategy and identification of eligible papers. 
For this systematic reviewed we searched: 
1.a Medline search strategy 	  
Database: Ovid MEDLINE(R) and Epub Ahead of Print, In-Process & Other Non-
Indexed Citations, Daily and Versions(R) <1946 to August 17, 2018> 
Search Strategy: 
-------------------------------------------------------------------------------- 
1     manec.mp. [mp=title, abstract, original title, name of substance word, subject 
heading word, floating sub-heading word, keyword heading word, protocol 
supplementary concept word, rare disease supplementary concept word, unique identifier, 
synonyms] (127) 
2     (Mixed adj2 adenoneuroendocrine).mp. [mp=title, abstract, original title, name of 
substance word, subject heading word, floating sub-heading word, keyword heading 
word, protocol supplementary concept word, rare disease supplementary concept word, 
unique identifier, synonyms] (159) 
3     (Mixed adj2 "adeno-neuroendocrine").mp. [mp=title, abstract, original title, name of 
substance word, subject heading word, floating sub-heading word, keyword heading 
word, protocol supplementary concept word, rare disease supplementary concept word, 
unique identifier, synonyms] (20) 
4     1 or 2 or 3 (197) 
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5     (amphicrine adj1 (carcinoma$1 or tumor$1 or tumour$1 or cancer$1 or 
neoplas$)).mp. [mp=title, abstract, original title, name of substance word, subject heading 
word, floating sub-heading word, keyword heading word, protocol supplementary 
concept word, rare disease supplementary concept word, unique identifier, synonyms] 
(43) 
6     4 or 5 (234) 
7     minen$1.mp. [mp=title, abstract, original title, name of substance word, subject 
heading word, floating sub-heading word, keyword heading word, protocol 
supplementary concept word, rare disease supplementary concept word, unique identifier, 
synonyms] (25) 
8     "Mixed neuroendocrine-nonneuroendocrine ".mp. [mp=title, abstract, original title, 
name of substance word, subject heading word, floating sub-heading word, keyword 
heading word, protocol supplementary concept word, rare disease supplementary concept 
word, unique identifier, synonyms] (7) 
9     "Mixed neuroendocrine-non-neuroendocrine ".mp. [mp=title, abstract, original title, 
name of substance word, subject heading word, floating sub-heading word, keyword 
heading word, protocol supplementary concept word, rare disease supplementary concept 
word, unique identifier, synonyms] (4) 
10     7 or 8 or 9 (28) 
11     6 or 10 (257) 
12     limit 11 to (english or french or german or italian or spanish) (219) 
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1 ( ( ( manec ) OR ( mixed PRE/2 adenoneuroendocrine ) OR ( mixed PRE/2 
“adenoneuroendocrine” ) ) OR ( TITLE-ABS-KEY ( minen ) ) OR ( TITLE-ABS-KEY ( 
“mixed neuroendocrine-nonneuroendocrine” ) ) OR ( TITLE-ABS-KEY ( “mixed 
neuroendocrine-non-neuroendocrine” ) ) ) AND NOT ( INDEX ( medline ) ) AND ( 
LIMIT-TO ( LANGUAGE, “English” ) OR LIMIT-TO ( LANGUAGE, “German” ) OR 
LIMIT-TO ( LANGUAGE, “ French” ) OR LIMIT-TO ( LANGUAGE,  “Spanish” ) ) 
 
2 ( ( ( manec ) OR ( mixed PRE/2 adenoneuroendocrine ) OR ( mixed PRE/2 
“adenoneuroendocrine” ) ) OR ( TITLE-ABS-KEY ( minen ) ) OR ( TITLE-ABS-KEY ( 
“mixed neuroendocrine-nonneuroendocrine” ) ) OR ( TITLE-ABS-KEY ( “mixed 
neuroendocrine-non-neuroendocrine” ) ) ) AND NOT ( INDEX ( medline ) ) 
 
3 INDEX ( medline ) 
4 ( ( ( manec ) OR ( mixed PRE/2 adenoneuroendocrine ) OR ( mixed PRE/2 
“adenoneuroendocrine” ) ) OR ( TITLE-ABS-KEY ( minen ) ) OR ( TITLE-ABS-KEY ( 
“mixed neuroendocrine-nonneuroendocrine” ) ) OR ( TITLE-ABS-KEY ( “mixed 
neuroendocrine-non-neuroendocrine” ) ) ) 
5 TITLE-ABS-KEY ( “mixed neuroendocrine-non-neuroendocrine” ) (187) 
 
1c. Embase serach strategy 
 
1  manec  (242) 
2 mixed NEXT/2 neuroendocrine (171)     
3 'mixed adeno-neuroendocrine' (38)               
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4 'minen':ti,ab,kw (18)                 
5 'mixed neuroendocrine-nonneuroendocrine' (8)              
6 'mixed neuroendocrine-non-neuroendocrine' (6)               
7 1 OR #2 OR #3 OR #4 OR #5 OR #6 (373)             
8 #7 AND [embase]/lim NOT ([embase]/lim AND [medline]/lim)  (225) 
 
	   
 
 
 
 
